Challenges in understanding Sjögren's syndrome - improved insights into the pathogenesis generate hope for innovative therapies?

Abstract

The reviews in this series on Sjögren syndrome provide an up-to-date summary and perspectives on the pathogenesis of this interesting entity with glandular and frequently systemic manifestations, the value of preclinical models, and our current understanding of therapeutic approaches. The last of these includes what has been learned from trials blocking tumor necrosis factor and, more recently, anti-CD20 therapy. Potential therapeutic targets, such as blockade of the B cell-activating factor, the role of interferon-alpha, and targeting CD22, are discussed.

This series on Sjögren syndrome, like disease-oriented review series on systemic lupus erythematosus (SLE) [1, 2], vasculitides, and comorbidities of rheumatic conditions [3], consists of articles that review recent topics, bring us up to date, and provide innovative views [4–8]. Respected researchers of rheumatology and clinical immunology with a great deal of experience in this particular systemic disease provide these overviews and share their perspectives. It is notable that the advent of innovative immune interventions in rheumatoid arthritis within the last decade and the recent approval of the anti-B cell-activating factor/B lymphocyte stimulator (anti-BAFF/BLyS) inhibitor belimumab for SLE have changed the lives of our patients and the treatment armament-tarium, but there is ongoing research for better therapeutic targets in Sjögren syndrome.

With this in mind, the authors of these reviews address central questions about the immunopathogenesis of Sjögren syndrome. Sipsas and colleagues [4] explore the potential role of retroviruses in initiating or maintaining disease. Vitali [5] examines the differences and similarities of sicca symptoms and risk of developing lymphoma between patients with HIV or hepatitis C virus infection and those with Sjögren syndrome. Low and Witte [6] investigate the central role of type I interferons (IFNs) driving innate immunity. Youinou and Pers [7] address the obvious abnormalities of other cytokines such as BAFF/BLyS, interleukin-17, and tumor necrosis factor-alpha (TNF-α) in the context of the local production in the inflamed salivary tissues.

While further insight into the pathogenesis of Sjögren syndrome in humans is of critical relevance to arrive at newer therapies, various preclinical models of either spontaneous or inducible Sjögren-like disease, as comprehensively reviewed by Delaleu and colleagues [8], are important for testing candidate therapeutics. In this context, the advantages and disadvantages of the different mice strains remind us of the different models of arthritis [9] and lupus [10]. While these aspects can be discussed at length, there is a possibility that even patients with Sjögren can represent such heterogeneity. Moreover, Kallenberg and colleagues [11] summarize the current data from various trials studying inhibition of TNF-α, IFN-α, BAFF, and anti-CD20 and -CD22 therapy and put this in the context of what these trials have to say about the immune abnormalities in Sjögren syndrome. With the continuous initiatives of identifying patients' profiles and responses [12], the information summarized in this review series could reflect the current understanding of the (immuno) pathogenesis of Sjögren syndrome and the therapeutic possibilities and limitations, which all may support our continuous search for improved therapies for this interdisciplinary disease.

Note

Autoimmune Basis of Rheumatic Diseases

This article is part of a series on Sjögren's syndrome, edited by Thomas Dörner, which can be found online at http://arthritis-research.com/series/Sjogrens

This series forms part of a special collection of reviews covering major autoimmune rheumatic diseases, available at: http://arthritis-research.com/series/abrd